What happened
Eli Lilly and Twist Bioscience are using AI in drug development in different ways. Lilly partners with OpenAI on drug discovery and has built an AI co-innovation lab with Nvidia to find molecules faster; Twist makes synthetic DNA that drugmakers test, and is now integrated into Amazon's new Bio Discovery platform for AI-driven drug design.
Why it matters
The first wave of AI rewarded companies that sold the tools. The next wave appears to reward companies that apply those tools in clinics, labs, and pharmacies to produce new medicines. Both firms show how AI adoption is moving into real-world use rather than staying at the software level.
What to watch
Eli Lilly's recently approved weight-loss pill Foundayo is a near-term growth driver because a pill format (replacing injections) could reach a much larger patient population. Twist reported revenue rising 19% to $110.7 million（約180億円） in fiscal Q2 2026 and has posted 13 straight quarters of rising revenue, though it currently operates at a net loss.
Ask the AI about this article →
For example, today's edition would include:
AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.
Free · takes 30 seconds · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. Q&As are published on this page for other readers too.
AI giants are leaning into health care as a strategy to stall public backlash, according to Axios
Global funding to biotech startups has held between $36 billion and $40 billion for the past few years, and 20…
Researchers at Lille University Hospital in France rigged an LLM-based diagnostic support system to suggest a…
Social media conversations about Tempus AI intensified after Moderna and Merck reported Phase 3 success in per…
A Pew Research Center survey of 3,488 U.S
Nurses rallied in downtown Asheville on Thursday, Aug
